Evidence map›Paper›PMID 25666675›Full record

ArticleThe Journal of investigative dermatology2015

Silencing autocrine death: a ubiquitin ligase that blocks activation-induced cell death in cutaneous T-cell lymphoma.

Claus-Detlev Klemke, Maria Feoktistova, Martin Leverkus

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Claus-Detlev KlemkeDepartments of Dermatology, Venereology, and Allergology, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany.
Maria FeoktistovaSection of Molecular Dermatology, Departments of Dermatology, Venereology, and Allergology, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany.
Martin LeverkusDepartments of Dermatology, Venereology, and Allergology, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany; Section of Molecular Dermatology, Departments of Dermatology, Venereology, and Allergology, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany. Electronic address: Martin.Leverkus@medma.uni-heidelberg.de.
Heidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous T-cell lymphoma (CTCL) tumor cells lack the ability of activated T cells to undergo TCR/CD3-mediated activation-induced cell death (AICD). In this issue, the study reported by Wu et al. demonstrates that c-CBL (Casitas B-lineage Lymphoma proto-oncogene) is overexpressed in CTCL. When CTCL cells lose c-CBL, AICD is enhanced. Furthermore, combination therapy with methotrexate (a known demethylating agent for the CD95 gene) in combination with the loss of c-CBL increases CTCL cell death. Therefore, inhibition of c-CBL could represent a method of sensitizing lymphoma cells to enhance AICD. Armed with their novel data, the investigators envision combination therapies that target c-CBL to reactivate AICD in the malignant T cells whenever responsiveness to TCR/CD3 signaling is retained.

Indexed as

ApoptosisFemaleGene Expression Regulation, NeoplasticHumansLymphoma, T-Cell, CutaneousMaleProto-Oncogene MasProto-Oncogene Proteins c-cblRNA, Small InterferingSkin NeoplasmsUp-RegulationCBL protein, humanMAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins c-cblRNA, Small Interfering

Identifiers

PMID25666675
OpenAlexW2017917786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.